17-alpha-Estradiol vs Enclomiphene

Mechanism

Non-feminizing estrogen that extends lifespan in male mice via metabolic improvements. Reduces hepatic mTOR signaling, improves glucose homeostasis, and reduces inflammation without estrogenic effects on reproductive tissues.

Contraindications

• Not FDA-approved for human use
• Theoretical hormone-sensitive cancer risk

Mechanism

Enclomiphene is the purified trans-isomer of clomiphene citrate that acts as a selective estrogen receptor antagonist at the hypothalamus and pituitary without the estrogenic agonist activity of the zuclomiphene isomer. By blocking estrogen receptor alpha (ERa) in the hypothalamus, it removes estradiol-mediated negative feedback on GnRH neurons, resulting in increased pulsatile GnRH release and consequent elevation of LH and FSH from the anterior pituitary. This stimulates endogenous Leydig cell testosterone production while preserving spermatogenesis — a critical advantage over exogenous testosterone.

Standard Dosing

Research indicates 12.5-25 mg daily orally for testosterone restoration in secondary hypogonadism.

Timing

Once daily, morning preferred. No food timing requirements. Consistent daily dosing for optimal HPG axis stimulation.

Cycle Duration

Long-term use (months to years) is feasible due to absence of zuclomiphene accumulation issues. Reassess every 3-6 months.

Side Effects

• Headache
• Hot flashes
• Nausea (less common than racemic clomiphene)
• Elevated estradiol (from increased testosterone substrate for aromatase)
• Rare visual disturbances (significantly less than racemic clomiphene)

Contraindications

• Primary hypogonadism (elevated gonadotropins, testicular failure)
• Severe hepatic impairment
• Known hypersensitivity to clomiphene isomers
• Pituitary tumors
• Vision changes or thrombotic history warrant caution

Best Stacking Partners